Ocuphire Pharma, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical Advisory Board
  • Product Pipeline
    • Overview
    • Nyxol
    • APX3330
    • APX2009
    • Posters and Publications
  • Clinical Trials
    • Overview
    • ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330 Recruiting Completed
    • MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects Completed
    • MIRA-3 Completed
    • MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol Completed
    • LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol Completed
    • VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine Completed
  • Partnerships
  • News & Media
    • Press Releases
    • Presentations
    • Events
    • Ocuphire in the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Ocuphire in the News

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
  • Ocuphire in the News

Ophthalmology Management eUpdate

Mar 9, 2022

Presbyopia Physician March 2022

Mar 1, 2022

The Latest Roundup of Key Presbyopia Correcting Drops

Feb 1, 2022
What Is the Optimal Pupil Size?

What Is the Optimal Pupil Size?

Jan 18, 2022
Presbyopia Physician November 2021

Presbyopia Physician November 2021

Nov 15, 2021

Highlights from American Academy of Ophthalmology Conference 2021

Nov 13, 2021
 With Vuity Approval, AbbVie Continues Stepping Into Eye Care- AbbVie Could Create Market For Other Presbyopia Players

With Vuity Approval, AbbVie Continues Stepping Into Eye Care- AbbVie Could Create Market For Other Presbyopia Players

Nov 3, 2021

Investigative Oral Retina Drug APX3330 Shows Favorable Safety, Tolerability

Oct 9, 2021

Ocuphire Recognized in Small Business Dealmakers Awards Honors

May 27, 2021

Presbyopia – A Review of Current Treatment Options and Emerging Therapies

May 24, 2021
RSS
  • 1
  • 2
  • 3
  • Next »
Ocuphire Pharma, Inc.
© Ocuphire Pharma, Inc. All rights reserved. Privacy Policy Disclaimer Sitemap Terms of Use